Mainz Biomed B.V.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Guido Baechler
- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Robert Koch Strasse 50 Mainz Germany 55129
- IPO Date
- Nov 5, 2021
- CIK
- 0001874252
- Website
- mainzbiomed.com
- Similar Companies
- Business
- Mainz Biomed N.V. develops and commercializes molecular genetic diagnostic solutions specializing in early cancer detection. The company's core product portfolio includes ColoAlert, a non-invasive, stool-based, DNA diagnostic test for early detection of colorectal cancer marketed across Europe; PancAlert, an early-stage pancreatic cancer screening test employing real-time PCR multiplex detection of molecular-genetic biomarkers in blood and stool samples; and a pipeline of next-generation mRNA-based colorectal cancer screening assays. Mainz Biomed provides clinical trial laboratory services and is advancing pivotal FDA studies through its ongoing eAArly DETECT 2 clinical trial in the United States. The company operates primarily in Europe and the United States, with headquarters near Frankfurt, Germany. Recent major developments include strategic collaborations with Thermo Fisher Scientific to co-develop next-generation colorectal cancer screening products leveraging Thermo Fisher's technology platforms and instrumentation. The company has entered distribution partnerships with Praxisdienst, Germany's largest online medical product retailer, and DoctorBox, a leading European digital health platform, to expand access to ColoAlert for home and preventive healthcare markets. Mainz Biomed also partnered with OncoVanguard8 to introduce ColoAlert in South America. In 2024, Mainz Biomed conducted a successful $8 million follow-on funding round to support ongoing product development and commercialization efforts. It has further collaborations with Quest Diagnostics in the U.S. for clinical trial support and semi-exclusive testing service rights, positioning the company for potential FDA market entry. Founded in 2008 and headquartered in Mainz, Germany, Mainz Biomed operates in the molecular diagnostics and healthcare technology sectors, focusing on developing innovative genetic tests for life-threatening cancers to facilitate early detection and improve patient outcomes. The company holds ISO 13485 certification for its ColoAlert manufacturing processes and is progressing toward regulatory approvals for U.S. market expansion. Its target markets include healthcare providers, diagnostic laboratories, and at-home testing consumers, with a growing international footprint through partnerships and clinical studies.
Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
Mainz Biomed NV (NASDAQ:MYNZ) Short Interest Update
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
2 Small-Cap Biotechs That Could Reward Patient Investors
Mainz Biomed (NASDAQ:MYNZ) Shares Down 5.8% – What’s Next?
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
Mainz Biomed Enters into Technology Partnership with EDX Medical Group